Three Finnish biotech companies – Abacus Diagnostica, Kaivogen and Labrox have joined forces to form Uniogen, a global frontrunner in in vitro diagnostics. The new company will provide the global market with a unique total solution for point-of-care testing, including diagnostics for infectious diseases and cancers. The next-generation solution will enable testing anywhere and at any time, thereby speeding up the the correct diagnosis and care. Instead of sending samples to external laboratories, samples are taken and analysed near the patient.
Uniogen company brings together some of the world’s leading instrumentation and biochemical knowhow. It will offer healthcare providers and patients faster, easier and more cost-effective diagnostics. The three growth companies have years of experience in diagnostics. The combined annual net sales of the three companies are approximately EUR 15 million. Uniogen employs about 100 employees and operates in 100 countries.
Tomi Numminen, Chairman of the Board of Uniogen, comments:
The team led by Sami Miettinen worked professionally on valuation and relative valuation and I can recommend them for similar projects.
Translink Corporate Finance acted as an independent financial advisor on the fairness of ownership structure. We published our Fairness Opinion and defended the outcome of the negotiations at the Annual General Meeting.
Read Uniogen press release on the merger.
View our recent references get to know our team.